S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
Surprise Yourself, Predict the Trends with A.I. (Ad)pixel
How to Play Apple and Amazon Heading in 2023
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
Surprise Yourself, Predict the Trends with A.I. (Ad)pixel
Microsoft strikes 10-year deal with Nintendo on Call of Duty
Could trawler cams help save world's dwindling fish stocks?
Bear Market Expert Reveals His #1 Stock for November 2023  (Ad)pixel
Southwest Airlines brings back dividend as travel rebounds
Closing prices for crude oil, gold and other commodities
S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
Surprise Yourself, Predict the Trends with A.I. (Ad)pixel
How to Play Apple and Amazon Heading in 2023
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
Surprise Yourself, Predict the Trends with A.I. (Ad)pixel
Microsoft strikes 10-year deal with Nintendo on Call of Duty
Could trawler cams help save world's dwindling fish stocks?
Bear Market Expert Reveals His #1 Stock for November 2023  (Ad)pixel
Southwest Airlines brings back dividend as travel rebounds
Closing prices for crude oil, gold and other commodities
S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
Surprise Yourself, Predict the Trends with A.I. (Ad)pixel
How to Play Apple and Amazon Heading in 2023
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
Surprise Yourself, Predict the Trends with A.I. (Ad)pixel
Microsoft strikes 10-year deal with Nintendo on Call of Duty
Could trawler cams help save world's dwindling fish stocks?
Bear Market Expert Reveals His #1 Stock for November 2023  (Ad)pixel
Southwest Airlines brings back dividend as travel rebounds
Closing prices for crude oil, gold and other commodities
S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
Surprise Yourself, Predict the Trends with A.I. (Ad)pixel
How to Play Apple and Amazon Heading in 2023
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
Surprise Yourself, Predict the Trends with A.I. (Ad)pixel
Microsoft strikes 10-year deal with Nintendo on Call of Duty
Could trawler cams help save world's dwindling fish stocks?
Bear Market Expert Reveals His #1 Stock for November 2023  (Ad)pixel
Southwest Airlines brings back dividend as travel rebounds
Closing prices for crude oil, gold and other commodities

PAVmed - PAVM Stock Forecast, Price & News

$0.62
+0.01 (+1.64%)
(As of 12/7/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.59
$0.64
50-Day Range
$0.61
$1.24
52-Week Range
$0.58
$3.66
Volume
624,150 shs
Average Volume
889,856 shs
Market Capitalization
$56.43 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.42

PAVmed MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
773.5% Upside
$5.42 Price Target
Short Interest
Healthy
6.11% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.78
Upright™ Environmental Score
News Sentiment
-1.59mentions of PAVmed in the last 14 days
Based on 3 Articles This Week
Insider Trading
Acquiring Shares
$104,780 Bought Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.23 out of 5 stars

Medical Sector

553rd out of 1,027 stocks

Surgical & Medical Instruments Industry

61st out of 101 stocks

PAVM stock logo

About PAVmed (NASDAQ:PAVM) Stock

PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a percutaneous device to treat carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE); and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay. Its product pipeline also comprises EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo, a disposable infusion platform technology; Veris cancer healthcare platform and implantable intelligent vascular port combining remote monitoring and data analytics; NextVent single-use ventilators; FlexMO medical circulatory support cannulas; Veris cardiac monitors; DisappEAR resorbable pediatric ear tubes; Solys noninvasive glucose monitoring. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.

Receive PAVM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PAVmed and its competitors with MarketBeat's FREE daily newsletter.

PAVM Stock News Headlines

PAVmed Inc. (PAVM) Q3 2022 Earnings Call Transcript
PAVmed to Participate in BTIG Digital Health Forum
Does PAVmed (NASDAQ:PAVM) Have A Healthy Balance Sheet?
See More Headlines
Receive PAVM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PAVmed and its competitors with MarketBeat's FREE daily newsletter.

PAVM Company Calendar

Last Earnings
8/12/2021
Today
12/07/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
4/04/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:PAVM
Fax
N/A
Employees
25
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$5.42
High Stock Price Forecast
$8.25
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+773.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-50,350,000.00
Pretax Margin
-17,406.02%

Debt

Sales & Book Value

Annual Sales
$500,000.00
Book Value
$0.88 per share

Miscellaneous

Free Float
78,168,000
Market Cap
$56.43 million
Optionable
Not Optionable
Beta
0.68

Key Executives

  • Dr. Lishan Aklog M.D. (Age 56)
    Chairman & CEO
    Comp: $1.24M
  • Mr. Dennis M. McGrath CPA (Age 65)
    Pres, CFO & Corp. Sec.
    Comp: $595.6k
  • Dr. Brian J. deGuzman M.D. (Age 57)
    Chief Medical Officer & Exec. VP of Clinical Affairs
    Comp: $427.6k
  • Mr. Shaun M. O'Neil M.B.A. (Age 40)
    Exec. VP & COO
  • Mr. Adrian K. Miller
    VP of Investor Relations













PAVM Stock - Frequently Asked Questions

Should I buy or sell PAVmed stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for PAVmed in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PAVM shares.
View PAVM analyst ratings
or view top-rated stocks.

What is PAVmed's stock price forecast for 2023?

2 brokers have issued twelve-month target prices for PAVmed's shares. Their PAVM share price forecasts range from $3.00 to $8.25. On average, they predict the company's share price to reach $5.42 in the next year. This suggests a possible upside of 773.5% from the stock's current price.
View analysts price targets for PAVM
or view top-rated stocks among Wall Street analysts.

How have PAVM shares performed in 2022?

PAVmed's stock was trading at $2.46 at the beginning of 2022. Since then, PAVM shares have decreased by 74.8% and is now trading at $0.6201.
View the best growth stocks for 2022 here
.

When is PAVmed's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 4th 2023.
View our PAVM earnings forecast
.

How were PAVmed's earnings last quarter?

PAVmed Inc. (NASDAQ:PAVM) released its earnings results on Thursday, August, 12th. The company reported ($0.14) earnings per share for the quarter, missing analysts' consensus estimates of ($0.10) by $0.04.

What other stocks do shareholders of PAVmed own?
What is PAVmed's stock symbol?

PAVmed trades on the NASDAQ under the ticker symbol "PAVM."

Who are PAVmed's major shareholders?

PAVmed's stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (4.07%), BlackRock Inc. (1.56%), Ergoteles LLC (0.23%), Bank of New York Mellon Corp (0.08%), Lido Advisors LLC (0.08%) and UBS Group AG (0.05%). Insiders that own company stock include Lishan Aklog, Matthew Sirovich, Michael J Glennon and Pavmed Inc.
View institutional ownership trends
.

How do I buy shares of PAVmed?

Shares of PAVM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is PAVmed's stock price today?

One share of PAVM stock can currently be purchased for approximately $0.62.

How much money does PAVmed make?

PAVmed (NASDAQ:PAVM) has a market capitalization of $56.43 million and generates $500,000.00 in revenue each year. The company earns $-50,350,000.00 in net income (profit) each year or ($0.98) on an earnings per share basis.

How can I contact PAVmed?

PAVmed's mailing address is ONE GRAND CENTRAL PLACE SUITE 4600, NEW YORK NY, 10165. The official website for the company is www.pavmed.com. The company can be reached via phone at (212) 949-4319 or via email at jmh@pavmed.com.

This page (NASDAQ:PAVM) was last updated on 12/8/2022 by MarketBeat.com Staff